Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
Sign Up to like & getrecommendations! Published in 2022 at "Internal medicine"
DOI: 10.2169/internalmedicine.0613-22
Abstract: The efficacy of benralizumab, as well as mepolizumab, to granulomatosis with polyangiitis (EGPA) involved with mononeuritis multiplex remains unclear. We experienced a case of EGPA presenting neuropathy with severe asthma. Muscle weakness due to neuropathy… read more here.
Keywords: efficacy; long term; granulomatosis polyangiitis; efficacy benralizumab ... See more keywords
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.865318
Abstract: Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma.… read more here.
Keywords: egpa benralizumab; efficacy benralizumab; benralizumab treatment; treatment ... See more keywords